Brought to you by 
Circassia gets US and Chinese rights to AIT's pulmonary hypertension system; deal terminated
31 May 2022
Executive Summary
AIT Therapeutics Inc. licensed Circassia Pharmaceuticals PLC commercial rights in the US and China to its AirNOvent cylinder free nitric oxide (NO) generator and phasic-flow delivery system for use in treating persistent pulmonary hypertension of the newborn (PPHN) and related indications in the hospital setting.
Deal Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Circassia gets US and Chinese rights to AIT's pulmonary hypertension system; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice